Quince Q2 FY26 net loss widens to $75.5 million

Reuters2026/08/14 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quince Therapeutics posted a GAAP net loss of USD 75.5 million, or USD 12.31 per share, for Q2 2026.
R&D expense fell 16.67% to USD 5.5 million; the decline reflected lower eDSP program costs, partly offset by higher LAM-001 startup spending.
G&A expense more than doubled to USD 16.6 million, driven by a USD 9.1 million non-cash stock-comp charge and higher professional fees.
Cash and cash equivalents totaled USD 116 million at June 30, 2026, following USD 103.6 million in net upfront private placement proceeds.
LAM-001 Phase 2 BOS data is expected in Q1 2027; Phase 2b PH-ILD data is expected in Q1 2028, with a SAPH Phase 2 start planned late 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED9810311) on August 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quince Q2 FY26 net loss widens to $75.5 million

You may also like

Crypto prices